trending Market Intelligence /marketintelligence/en/news-insights/trending/3rxrtan_azolgy3skuz8-a2 content esgSubNav
In This List

EyePoint Pharmaceuticals elects new board chairman

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


EyePoint Pharmaceuticals elects new board chairman

EyePoint Pharmaceuticals Inc., a specialty biopharmaceutical company, elected Göran Ando to be the chairman of the company's board.

Ando was appointed to the board in June 2018, according to a Sept. 10 press release. He previously held positions with Pfizer Inc., held several senior appointments at GlaxoSmithKline PLC, and most recently served as the CEO for Celltech Group Ltd.

As part of the transition, David Mazzo will step down as the non-executive chairman but will remain on the board.